Dashboard
Manage Tickers

PAVM PAVmed Inc.

Nasdaq pavmed.com


$ 0.35 $ -0.04 (-9.11 %)    

Thursday, 20-Nov-2025 14:06:45 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
QQQ $ 589.15 $ -22.52 (-3.68 %)
DIA $ 459.50 $ -7.25 (-1.55 %)
SPY $ 655.70 $ -17.20 (-2.56 %)
TLT $ 89.21 $ 0.22 (0.25 %)
GLD $ 375.18 $ 0.00 (0 %)
$ 0.3866
$ 0.39
$ 0.35 x 1,139
$ 0.35 x 1,000
$ 0.34 - $ 0.39
$ 0.30 - $ 1.25
421,205
na
11.47M
$ 1.79
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-12-2025 09-30-2025 10-Q
2 08-14-2025 06-30-2025 10-Q
3 05-15-2025 03-31-2025 10-Q
4 03-24-2025 12-31-2024 10-K
5 11-14-2024 09-30-2024 10-Q
6 08-12-2024 06-30-2024 10-Q
7 05-13-2024 03-31-2024 10-Q
8 03-25-2024 12-31-2023 10-K
9 11-13-2023 09-30-2023 10-Q
10 08-14-2023 06-30-2023 10-Q
11 05-15-2023 03-31-2023 10-Q
12 03-14-2023 12-31-2022 10-K
13 11-14-2022 09-30-2022 10-Q
14 08-15-2022 06-30-2022 10-Q
15 05-16-2022 03-31-2022 10-Q
16 04-06-2022 12-31-2021 10-K
17 11-22-2021 09-30-2021 10-Q
18 08-16-2021 06-30-2021 10-Q
19 05-17-2021 03-31-2021 10-Q
20 03-15-2021 12-31-2020 10-K
21 11-06-2020 09-30-2020 10-Q
22 08-14-2020 06-30-2020 10-Q
23 05-28-2020 03-31-2020 10-Q
24 04-14-2020 12-31-2019 10-K
25 11-19-2019 09-30-2019 10-Q
26 08-14-2019 06-30-2019 10-Q
27 05-15-2019 03-31-2019 10-Q
28 04-01-2019 12-31-2018 10-K
29 11-14-2018 09-30-2018 10-Q
30 08-13-2018 06-30-2018 10-Q
31 05-21-2018 03-31-2018 10-Q
32 03-14-2018 12-31-2017 10-K
33 11-14-2017 09-30-2017 10-Q
34 08-11-2017 06-30-2017 10-Q
35 05-22-2017 03-31-2017 10-Q
36 02-16-2017 12-31-2016 10-K
37 11-10-2016 09-30-2016 10-Q
38 08-12-2016 06-30-2016 10-Q
39 05-11-2016 03-31-2016 10-Q
40 04-11-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

pavmed-q3-adj-eps-002-beats-020-estimate-sales-5000k-miss-12500k-estimate
PAVmed Q3 Adj. EPS $(0.02) Beats $(0.20) E...
11/13/2025 13:48:02

PAVmed (NASDAQ:PAVM) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.20) by 90 ...

earnings-scheduled-for-november-13-2025
Earnings Scheduled For November 13, 2025
11/13/2025 11:11:32

ascendiant-capital-maintains-buy-on-pavmed-raises-price-target-to-20
Ascendiant Capital Maintains Buy on PAVmed...
10/06/2025 10:02:55

Ascendiant Capital analyst Edward Woo maintains PAVmed (NASDAQ:PAVM) with a Buy and raises the price target from $19 to $20.

Core News & Articles
Lucid Diagnostics Announces $25M Public Of...
09/10/2025 12:07:15

 Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical...

Core News & Articles
Lucid Diagnostics Reveals Proposed Public ...
09/09/2025 20:02:40

NEW YORK, Sept. 9, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a comm...

pavmed-announces-it-has-signed-a-non-binding-loi-with-duke-university-to-license-advanced-esophageal-precancer-detection-technology-through-a-new-subsidiary
PAVmed Announces It Has Signed A Non-Bindi...
08/26/2025 12:08:48

Newly-formed PAVmed subsidiary to license endoscopic imaging technology designed to identify and facilitate ablative treatment ...

pavmed-q2-adj-eps-005-beats-013-estimate-sales-6000k-miss-10000k-estimate
PAVmed Q2 Adj. EPS $(0.05) Beats $(0.13) E...
08/14/2025 12:01:57

PAVmed (NASDAQ:PAVM) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.13) by 61....

Core News & Articles
Earnings Scheduled For August 14, 2025
08/14/2025 08:32:32

Core News & Articles
Lucid Diagnostics, a PAVmed Subsidiary, Ne...
07/16/2025 11:35:15

Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical ...

ascendiant-capital-maintains-buy-on-pavmed-lowers-price-target-to-19
Ascendiant Capital Maintains Buy on PAVmed...
06/06/2025 10:29:24

Ascendiant Capital analyst Edward Woo maintains PAVmed (NASDAQ:PAVM) with a Buy and lowers the price target from $19.5 to $19.

pavmed-subsidiary-veris-health-enters-into-strategic-partnership-agreement-with-ohio-state-university-comprehensive-cancer-center-to-utilize-and-develop-commercialization-of-veris-cancer-care-platform-and-implantable-physiologic-monitor
PAVmed Subsidiary, Veris Health, Enters In...
06/03/2025 12:36:37

pavmed-q1-adj-eps-007-beats-013-estimate-sales-800k-miss-1000k-estimate
PAVmed Q1 Adj. EPS $(0.07) Beats $(0.13) E...
05/15/2025 12:02:18

PAVmed (NASDAQ:PAVM) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.13) by 46....

Core News & Articles
Earnings Scheduled For May 15, 2025
05/15/2025 08:32:23

pavmeds-earnings-a-preview
PAVmed's Earnings: A Preview
05/14/2025 19:02:56

ascendiant-capital-maintains-buy-on-pavmed-raises-price-target-to-195
Ascendiant Capital Maintains Buy on PAVmed...
04/21/2025 10:16:32

Ascendiant Capital analyst Edward Woo maintains PAVmed (NASDAQ:PAVM) with a Buy and raises the price target from $19 to $19.5.

12-health-care-stocks-moving-in-mondays-pre-market-session
12 Health Care Stocks Moving In Monday's P...
03/31/2025 12:05:38

pavmed-q4-2024-adj-eps-006-beats-057-estimate-sales-1000k-miss-58000k-estimate
PAVmed Q4 2024 Adj EPS $(0.06) Beats $(0.5...
03/25/2025 12:03:12

PAVmed (NASDAQ:PAVM) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.57) by 89....

earnings-scheduled-for-march-25-2025
Earnings Scheduled For March 25, 2025
03/25/2025 08:32:09

Core News & Articles
Lucid Diagnostics Announced NCCN Guideline...
03/20/2025 12:35:52

Highlights society guidelines recommending non-endoscopic biomarker testing, such as Lucid's EsoGuard Esophageal DNA Test, ...

Core News & Articles
Lucid Diagnostics' ENVET-BE Clinical Utili...
03/18/2025 12:34:50

Study confirms clinical utility of EsoGuard as a non-invasive triage tool to significantly increase positive yield of invasive ...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION